Cellicon Valley: Building A Thriving Cell and Gene Therapy Ecosystem Leveraging Academia and Industry in Greater Philadelphia
May 27 – 17:00 ET
Symposium Hosted By:

John S. Swartley, MBA, PhD
Session Chair

University of Pennsylvania
Penn Center of Innovation
United States

Steven Nichtberger, MD
Cabaletta Bio

United States

Steven Kelly, BS, MBA
Carisma Therapeutics

United States

Usman “Oz” Azman, MD

United States

Since the founding of America’s first hospital, Pennsylvania Hospital, by Benjamin Franklin and Dr. Thomas Bond in 1751, Philadelphia has had a longstanding commitment to healthcare innovation.

Today, that legacy lives on in Philadelphia and is exemplified by the emergence of numerous paradigm shifting and life-changing medicines including the first gene therapy approved by the U.S. Food and Drug Administration (FDA), Kymriah™, as well as the first directly administered gene therapy approved in the U.S. that targeted a disease caused by mutations in a specific gene, LUXTURNA™. Both therapies are based on fundamental technology breakthroughs from the University of Pennsylvania and the Children’s Hospital of Philadelphia (CHOP), and both were developed in close partnership with industrial collaborators helping to drive the emergence of “Cellicon Valley” in Philadelphia over the last decade.

More than just a name, “Cellicon Valley” is home to world-class academic research institutions that bring in over $1B in NIH funded research dollars per year, more than 35 leading cell and gene therapy companies that have collectively raised collectively raised over $1.5B in capital in 2020, and over 1.5 million square feet of new lab space currently in development. This burgeoning ecosystem is a unique environment that truly leverages academia and industry to foster the needed skills and experience to further innovate, test, and commercialize new therapies.

Join us to learn more about the origins, models for collaboration, and future direction of “Cellicon Valley”.